The Latest Breaking News from Obesity

Novo Nordisk has lost about a quarter of its value since the end of June. Meanwhile, indications are that its diabetes and weight-loss drugs may be useful in fighting cardiovascular disease, arthritis, opioid and alcohol addiction, and Alzheimer's. Novo remains a leader in the sector, and is trading at a…

Labour’s plans to give weight loss drugs to the unemployed may not just fail: it could backfire, therapist Sally Baker explains

Scientists have developed a novel blood test that uses lipids to identify children who are more susceptible to obesity-related problems like diabetes. Read further on Dynamite News:

The study noted that a vast majority of obese patients, strikingly 94.7%, received neither form of treatment, while 5% received GLP-1 RAs and 0.3% received surgery.

Exclusive: Stéfan Descheemaeker of Nomad Foods says mandatory rules could help kickstart ‘nutrition arms race’

Ozempic and other GLP-1 drugs have proved to be revolutionary in managing the epidemic of obesity, treating diabetes, and somewhat reducing the risk of many chronic diseases. Studies are now proving its efficacy in improving brain health. According to a new study published in the journal Alzheimer's Dementia, Semaglutide, the…

The medicines regulator has also urged medics to warn patients of side effects.

The proposals came from the Lords’ Food, Diet and Obesity Committee.

Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval for a new eczema drug called Ebglyss. As the company expands its reach in the diabetes, obesity, and eczema markets, is it a must-have in your healthcare portfolio? Read on to…